DL-Tubasaeure | 56401-12-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: DL-Tubasaeure
• 英文别名: 4-Hydroxy-2-(1-methylethenyl)-2,3-dihydrobenzofuran-5-carboxylic acid；4-hydroxy-2-prop-1-en-2-yl-2,3-dihydro-1-benzofuran-5-carboxylic acid
• CAS: 56401-12-8
• 化学式: C₁₂H₁₂O₄
• mdl: MFCD28336786
• 分子量: 220.225
• InChiKey: CMXGHLJKXLIMAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Methods for preparation and use of psorospermin analogs
  申请人：——

  公开号：US20030120093A1

  公开（公告）日：2003-06-26

  Psorospermin is a cytotoxic dihydroflranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin analogs to inhibit cellular proliferation.

  Psorospermin是一种细胞毒性二氢黄酮黄酮类化合物，已被发现对各种肿瘤细胞系表现出显著的活性。不幸的是，psorospermin从其天然植物来源中已不再容易获得。本发明涉及一种制备psorospermin和psorospermin类似物的方法。还公开了利用psorospermin类似物抑制细胞增殖的方法。
• METHODS FOR PREPARATION AND USE OF PSOROSPERMIN ANALOGS
  申请人：Board of Regents,The University of Texas System

  公开号：EP1395596A2

  公开（公告）日：2004-03-10
• Methods and compositions for treating metabolic disorders
  申请人：Mootha Vamsi Krishna

  公开号：US20090143279A1

  公开（公告）日：2009-06-04

  The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.
• SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST
  申请人：Califano Andrea

  公开号：US20090269772A1

  公开（公告）日：2009-10-29

  Systems, methods, and apparatus for searching for a combination of compounds of therapeutic interest are provided. Cell-based assays are performed, each cell-based assay exposing a different sample of cells to a different compound in a plurality of compounds. From the cell-based assays, a subset of the tested compounds is selected. For each respective compound in the subset, a molecular abundance profile from cells exposed to the respective compound is measured. Targets of transcription factors and post-translational modulators of transcription factor activity are inferred from the molecular abundance profile data using information theoretic measures. This data is used to construct an interaction network. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the subset of compounds. The drug activity profiles are used to form a filter set of compound combinations from the subset of compounds.
• US7244760B2
  申请人：——

  公开号：US7244760B2

  公开（公告）日：2007-07-17